Results 111 to 120 of about 319,869 (211)

Cost-Effectiveness Analysis of Trastuzumab-Emtansine as Adjuvant Therapy for HER2-Positive Early Breast Cancer with Residual Invasive Disease in Colombia. [PDF]

J Health Econ Outcomes Res
Samacá-Samacá D, Ballén D, Lombana M, Díaz-Puentes M, Cáceres-Maldonado SA, Saavedra J, Prieto-Pinto L.   +6 more
europepmc   +1 more source

rWTC‐MBTA Vaccine, Alone and Enhanced with Anti‐PD1, Elicits Immune Responses against CNS and Peripheral B‐Cell Lymphoma

Advanced Science, EarlyView.
An autologous whole‐tumor‐cell vaccine (rWTC‐MBTA) is evaluated in murine CNS lymphoma. Subcutaneous vaccination activates dendritic cells, broadens T‐cell priming, and drives lymphocyte trafficking to brain tumors, producing durable tumor control. Longitudinal bioluminescence and adoptive‐transfer assays verify CNS engagement. Combination with anti‐PD‐
Yaping Zhang, Juan Ye, Mitchell Sun, Samik Chakraborty, Alex Valenzuela, Shuran Chen, Qingfeng Xue, Wenyu Shi, Karel Pacak, Herui Wang, Zhengping Zhuang   +10 more
wiley   +1 more source

Combined Approach (Surgery + Systemic Adjuvant Therapy) in a Giant Cell Tumor of Proximal Femur: A Rare Case Report. [PDF]

J Orthop Case Rep
Mohandas P, Magadum SD, Manickavasagam M.   +2 more
europepmc   +1 more source

Engineering Osteoimmune Responses with Functionalized Orthopedic Implants for Post‐Operative Osteosarcoma Treatment

Advanced Science, EarlyView.
Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong, Lingshuang Wang, Hui Zhang, Menghuan Li, Zhong Luo, Yan Hu, Chunyuan Cai   +6 more
wiley   +1 more source

Comment on "Prognostic impact of adjuvant therapy following surgical resection in primary hepatic sarcomatoid carcinoma ". [PDF]

Int J Surg
Xiang Q, Fu X, Sun X.
europepmc   +1 more source

Extracellular Vesicles of Streptococcus anginosus Mediate Gastritis via Epithelial Barrier Disruption and Macrophage‐driven Inflammation

Advanced Science, EarlyView.
Streptococcus anginosus extracellular vesicles (SA‐EVs) accumulate in gastric tissue, disrupt epithelial tight junctions, and induce gastritis characterized by neutrophil infiltration and elevated cytokines (TNF‐α, IL‐6, IL‐17A). Proteomics identifies TMPC and FBP62 as key SA‐EVs virulence factors; their genetic deletion attenuates inflammation ...
Ying Gong, Lina Duan, Jie Xiao, Yulu Deng, Hongxia Wang, Yajie Zhang, Xiumei Hu, Haifang Wang, Taixue An, Xin Li, Yurong Qiu, Lei Zheng, Haixia Li   +12 more
wiley   +1 more source

Postoperative adjuvant therapy for driver gene-positive non-small-cell lung cancer patients. [PDF]

Chin Med J (Engl)
Lung Cancer Treatment Collaboration Group, Chinese Medical Association.   +1 more
europepmc   +1 more source

Selective Targeting of Tip Endothelial Cells as a Therapeutic Strategy for Tumor Angiogenesis

Advanced Science, EarlyView.
Doppel protein is selectively expressed in tip endothelial cells within the tumor vasculature, where it promotes tip cell motility and stabilizes the tip cell phenotype. Targeting Doppel with monoclonal antibodies disrupts this stabilization, impairs angiogenic sprouting, and reduces tumor angiogenesis, offering a selective and druggable switch for ...
Byoungmo Kim, Ha Kyeong Lee, Zulfikar Azam, Jeong Uk Choi, Riajul Wahab, Na Kyeong Lee, Yoon Gun Ko, So‐Young Choi, Se‐Ra Lee, Wan Seob Shim, Taeeung Kim, In‐San Kim, Farzana Alam, Sang Yoon Kim, Seong Who Kim, Youngro Byun, Taslim A Al‐Hilal   +16 more
wiley   +1 more source

Naltrexone/Bupropion, Liraglutide, or Semaglutide as Adjuvant Therapy After Metabolic and Bariatric Surgery: An Observational Study. [PDF]

Obes Sci Pract
Brancatisano A, Ryan B.
europepmc   +1 more source

TriCON: A Carbon‐Based Triple‐Modal Nanoplatform for Pancreatic Cancer Therapy

Advanced Science, EarlyView.
We developed TriCON, a triple‐modality nanotherapeutic platform, to treat pancreatic ductal adenocarcinoma (PDAC) by synergizing gene editing, chemotherapy, and immunotherapy. TriCON utilizes CRISPR/Cas9 to target the poliovirus receptor (PVR), combined with nano‐encapsulated doxorubicin and checkpoint blockade. This approach achieved significant tumor
Xinyu Peng, Jiaxing Huang, Shengnan Lv, Jian Zhang, Liangliang Zhang, Huan Liu, Yan Liu, Zhen‐An Qiao, Feng Wei, Bao‐Lian Su   +9 more
wiley   +1 more source